Merck Basic EPS 2012-2026 | MRK
Merck annual/quarterly basic eps history and growth rate from 2012 to 2026. Basic eps can be defined as a company's net earnings or losses attributable to common shareholders per basic share basis.
- Merck basic eps for the quarter ending March 31, 2026 was $0.00, a 100% decline year-over-year.
- Merck basic eps for the twelve months ending March 31, 2026 was $4.08, a 40.78% decline year-over-year.
- Merck annual basic eps for 2025 was $0B, a 100% decline from 2024.
- Merck annual basic eps for 2024 was $0.007B, a 4728.57% increase from 2023.
- Merck annual basic eps for 2023 was $0B, a 97.56% decline from 2022.
| Merck Annual Basic EPS | |
|---|---|
| 2025 | |
| 2024 | $6.76 |
| 2023 | $0.14 |
| 2022 | $5.73 |
| 2021 | $5.16 |
| 2020 | $2.79 |
| 2019 | $3.84 |
| 2018 | $2.34 |
| 2017 | $0.88 |
| 2016 | $1.42 |
| 2015 | $1.58 |
| 2014 | $4.12 |
| 2013 | $1.49 |
| 2012 | $2.03 |
| 2011 | $2.04 |
| Merck Quarterly Basic EPS | |
|---|---|
| 2026-03-31 | |
| 2025-12-31 | |
| 2025-09-30 | $2.32 |
| 2025-06-30 | $1.76 |
| 2025-03-31 | $2.01 |
| 2024-12-31 | $1.48 |
| 2024-09-30 | $1.25 |
| 2024-06-30 | $2.15 |
| 2024-03-31 | $1.88 |
| 2023-12-31 | $-0.49 |
| 2023-09-30 | $1.87 |
| 2023-06-30 | $-2.35 |
| 2023-03-31 | $1.11 |
| 2022-12-31 | $1.19 |
| 2022-09-30 | $1.28 |
| 2022-06-30 | $1.56 |
| 2022-03-31 | $1.70 |
| 2021-12-31 | $1.48 |
| 2021-09-30 | $1.81 |
| 2021-06-30 | $0.61 |
| 2021-03-31 | $1.26 |
| 2020-12-31 | $-0.83 |
| 2020-09-30 | $1.16 |
| 2020-06-30 | $1.19 |
| 2020-03-31 | $1.27 |
| 2019-12-31 | $0.93 |
| 2019-09-30 | $0.74 |
| 2019-06-30 | $1.04 |
| 2019-03-31 | $1.13 |
| 2018-12-31 | $0.70 |
| 2018-09-30 | $0.73 |
| 2018-06-30 | $0.64 |
| 2018-03-31 | $0.27 |
| 2017-12-31 | $-0.37 |
| 2017-09-30 | $-0.02 |
| 2017-06-30 | $0.71 |
| 2017-03-31 | $0.56 |
| 2016-12-31 | $-0.22 |
| 2016-09-30 | $0.79 |
| 2016-06-30 | $0.44 |
| 2016-03-31 | $0.41 |
| 2015-12-31 | $0.35 |
| 2015-09-30 | $0.65 |
| 2015-06-30 | $0.24 |
| 2015-03-31 | $0.34 |
| 2014-12-31 | $2.54 |
| 2014-09-30 | $0.31 |
| 2014-06-30 | $0.69 |
| 2014-03-31 | $0.58 |
| 2013-12-31 | $0.28 |
| 2013-09-30 | $0.38 |
| 2013-06-30 | $0.30 |
| 2013-03-31 | $0.53 |
| 2012-12-31 | $0.30 |
| 2012-09-30 | $0.57 |
| 2012-06-30 | $0.59 |
| 2012-03-31 | $0.57 |
| 2011-12-31 | $0.50 |
| 2011-09-30 | $0.55 |
| 2011-06-30 | $0.65 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $299.893B | $65.011B |
| Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |